Search Results - "Su, C W"

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study by Kelley, R.K., Verslype, C., Cohn, A.L., Yang, T.-S., Su, W.-C., Burris, H., Braiteh, F., Vogelzang, N., Spira, A., Foster, P., Lee, Y., Van Cutsem, E.

“…Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular…”
Get full text

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis by Papadimitrakopoulou, V.A., Mok, T.S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S.S., Kim, S.W., Shepherd, F.A., Laskin, J., He, Y., Akamatsu, H., Theelen, W.S.M.E., Su, W.-C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., Wu, Y.-L.

“…In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged…”
Get full text

Hepatitis C virus infection: a risk factor for Parkinson's disease by Wu, W. Y.-Y., Kang, K.-H., Chen, S. L.-S., Chiu, S. Y.-H., Yen, A. M.-F., Fann, J. C.-Y., Su, C.-W., Liu, H.-C., Lee, C.-Z., Fu, W.-M., Chen, H.-H., Liou, H.-H.

“…Summary Recent studies found that hepatitis C virus (HCV) may invade the central nervous system, and both HCV and Parkinson's disease (PD) have in common the…”
Get full text

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC by Yu, H A, Baik, C, Kim, D-W, Johnson, M L, Hayashi, H, Nishio, M, Yang, J C-H, Su, W-C, Gold, K A, Koczywas, M, Smit, E F, Steuer, C E, Felip, E, Murakami, H, Kim, S-W, Su, X, Sato, S, Fan, P-D, Fujimura, M, Tanaka, Y, Patel, P, Sternberg, D W, Sellami, D, Jänne, P A

“…Human epidermal growth factor receptor 3 (HER3) is broadly expressed in non-small-cell lung cancer (NSCLC) and is the target of patritumab deruxtecan…”
Get more information

Sp1 expression regulates lung tumor progression by Hsu, T-I, Wang, M-C, Chen, S-Y, Yeh, Y-M, Su, W-C, Chang, W-C, Hung, J-J

“…The role of specificity protein 1 (Sp1) in controlling gene expression in lung tumor development and metastasis is not well understood. In this study, we…”
Get full text

Letter: the role of direct‐acting anti‐virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus‐induced cirrhosis by Kao, W.‐Y., Su, C.‐W.

“…Linked content This article is linked to Mettke et al and Mettke and Wedemeyer papers. To view these articles visit https://doi.org/10.1111/apt.14427 and…”
Get full text

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) by De Santis, M., Wiechno, P.J., Bellmunt, J., Lucas, C., Su, W.-C., Albiges, L., Lin, C.-C., Senkus-Konefka, E., Flechon, A., Mourey, L., Necchi, A., Loidl, W.C., Retz, M.M., Vaissière, N., Culine, S.

“…There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the…”
Get full text

Flexible low-temperature polycrystalline silicon thin-film transistors by Chang, T.-C., Tsao, Y.-C., Chen, P.-H., Tai, M.-C., Huang, S.-P., Su, W.-C., Chen, G.-F.

“…In today's society, displays are indispensable for digital interaction and personal contact. Therefore, the development of displays is an urgent need for the…”
Get full text

Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion by YEH, H.-H, LAI, W.-W, CHEN, H. H. W, LIU, H.-S, SU, W.-C

“…Malignant pleural effusion (MPE) is a poor prognostic sign for patients with non-small-cell lung cancer (NSCLC). The generation of MPE is largely regulated by…”
Get full text

Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34 346 subjects by Wu, W.-C., Wu, C.-Y., Wang, Y.-J., Hung, H.-H., Yang, H.-I., Kao, W.-Y., Su, C.-W., Wu, J.-C., Chan, W.-L., Lin, H.-C., Lee, F.-Y., Lee, S.-D.

“…Summary Background The sensitivity of current upper limit of normal (ULN) of serum alanine aminotransferase (ALT) levels for detecting chronic liver disease…”
Get full text

Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer by Jen, J, Lin, L-L, Chen, H-T, Liao, S-Y, Lo, F-Y, Tang, Y-A, Su, W-C, Salgia, R, Hsu, C-L, Huang, H-C, Juan, H-F, Wang, Y-C

“…ZNF322A encoding a classical Cys2His2 zinc finger transcription factor was previously revealed as a potential oncogene in lung cancer patients. However, the…”
Get full text

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer by Gerber, D.E., Horn, L., Boyer, M., Sanborn, R., Natale, R., Palmero, R., Bidoli, P., Bondarenko, I., Germonpre, P., Ghizdavescu, D., Kotsakis, A., Lena, H., Losonczy, G., Park, K., Su, W -C, Tang, M., Lai, J., Kallinteris, N.L., Shan, J.S., Reck, M., Spigel, D.R.

“…Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This…”
Get full text

EGF-mediated inhibition of ubiquitin-specific peptidase 24 expression has a crucial role in tumorigenesis by Wang, S-A, Wang, Y-C, Chuang, Y-P, Huang, Y-H, Su, W-C, Chang, W-C, Hung, J-J

“…In this study, several cancer-related proteins (Bax, p300, E2F4 and securin) have been proven to be substrates of ubiquitin-specific peptidase 24 (USP24), and…”
Get full text

MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy by Hsu, T-I, Lin, S-C, Lu, P-S, Chang, W-C, Hung, C-Y, Yeh, Y-M, Su, W-C, Liao, P-C, Hung, J-J

“…Nucleolin (NCL) participates in DNA transcription, ribosomal biogenesis and the regulation of RNA stability. However, the contribution of NCL to tumor…”
Get full text

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma by Shiah, H.‐S., Chen, C.‐Y., Dai, C.‐Y., Hsiao, C.‐F., Lin, Y.‐J., Su, W.‐C., Chang, J.‐Y., Whang‐Peng, J., Lin, P.‐W., Huang, J.‐D., Chen, L.‐T.

“…Summary Background Deregulation of mammalian target of rapamycin (mTOR) signalling is common in human hepatocellular carcinoma (HCC). Aim To determine the…”
Get full text

The challenge and future of rocky desertification control in karst areas in southwest China by Zhang, J Y, Dai, M H, Wang, L C, Zeng, C F, Su, W C

“…Karst rocky desertification occurs after vegetation deteriorates as a result of intensive land use, which leads to severe water loss and soil erosion and…”
Get full text

Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA) by Chen, Y.-Y., Park, J.O., Su, W.-C., Oh, D.-Y., Kim, K.-P., Feng, Y.-H., Shen, L., Liao, H., Nie, J., Qing, M., Li, J., De Porre, P.

Get full text

Cancer risk in patients with pyogenic liver abscess: a nationwide cohort study by Kao, W.-Y., Hwang, C.-Y., Chang, Y.-T., Su, C.-W., Hou, M.-C., Lin, H.-C., Lee, F.-Y., Lee, S.-D., Wu, J.-C.

“…Summary Background There has been no large‐scale population‐based study on the relationship between pyogenic liver abscesses (PLA) and subsequent cancer risk…”
Get full text

Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy by Kao, W.-Y, Chiou, Y.-Y, Hung, H.-H, Su, C.-W, Chou, Y.-H, Wu, J.-C, Huo, T.-I, Huang, Y.-H, Wu, W.-C, Lin, H.-C, Lee, S.-D

“…Aims To evaluate the clinical inference of serum alpha-fetoprotein (AFP) response in hepatocellular carcinoma (HCC) patients undergoing percutaneous…”
Get full text

Dose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC) by Santoro, A., Su, W.-C., Navarro, A., Simonelli, M., Yang, J.C.-H., Ardizzoni, A., Barlesi, F., Kang, J.H., Didominick, S., Abdelhady, A., Goswami, B., Crystal, A., Felip, E.

Get full text